NMDA Receptor Antagonists Modulate Synapse Numbers for Social Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for better understanding of molecular mechanisms underlying Lethal Giant Larvae (Lgl1)-mediated excitotoxic neurodegeneration and associated diseases, as well as effective methods for preventing, managing, and treating neurodegenerative disorders resulting from Lgl1-mediated excitotoxicity, such as Smith-Magenis Syndrome (SMS), autism, and attention deficit hyperactivity disorder (ADHD).
Innovation Solution
A method involving the use of subanesthetic amounts of N-methyl-D-aspartate (NMDA) receptor antagonists, such as ketamine, memantine, or dizocilpine, to reduce or prevent increased synapses in neurons, combined with atypical protein kinase C (aPKC) inhibitors and Lgl1 agonists to modulate synapse formation and maintenance, thereby alleviating social interaction deficits associated with these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NMDA receptor antagonists are used to block abnormal NMDA receptor activity, then social interaction deficits are alleviated, but synapse numbers decrease
Solution Approach 1:
The patent changes the functional parameter of NMDA receptors by using antagonists to block abnormal activity, thereby improving social interaction deficits despite the reduction in synapse numbers. This parameter change approach targets the functional state rather than the quantity of synapses.
Solution Approach 2:
Instead of trying to increase synapse numbers to improve social interaction, the patent uses the opposite approach by blocking NMDA receptor activity, which inadvertently reduces synapse numbers while still achieving improvement in social interaction function.
2Reliability
If subanesthetic amounts of NMDA receptor antagonists are administered, then AMPA/NMDA ratio increases, but anesthetic effects are avoided
Solution Approach 1:
The patent uses subanesthetic amounts of NMDA receptor antagonists, which is a partial action approach. This dose level is sufficient to achieve therapeutic effects by increasing the AMPA/NMDA ratio but insufficient to cause anesthetic side effects, thus optimizing the benefit-risk profile.
Solution Approach 2:
By administering subanesthetic doses, the patent changes the dosage parameter to achieve a therapeutic window where the AMPA/NMDA ratio is increased sufficiently for therapeutic effect while remaining below the threshold for anesthetic side effects.
3Reliability
If aPKC inhibitors are used to modulate synapse formation, then synapse numbers are reduced, but therapeutic benefit is achieved
Solution Approach 1:
The patent introduces aPKC inhibitors as an intermediary mechanism to modulate synapse formation. These inhibitors act as mediators that reduce synapse numbers through the aPKC signaling pathway, thereby achieving therapeutic benefit without directly targeting synapses.
Solution Approach 2:
The patent replaces direct mechanical or structural approaches to synapse modulation with a biochemical mechanism using aPKC inhibitors. This substitution allows for more precise and controllable modulation of synapse formation through cellular signaling pathways.
Data Source
AI summary
The present invention is based on the finding that subanesthetic doses of N-methyl-D-aspartate (NMDA) receptor antagonists alleviate social interaction deficits associated with behavioral disorders, such as Smith-Magenis Syndrome (SMS). The invention therefore provides methods and compositions for treating SMS. Also provided are methods of selecting NMDA receptor agonists useful in alleviating social interaction deficits associated with such behavioral disorders.